Rossby Financial LCC Invests $228,000 in Agilent Technologies, Inc. (NYSE:A)

Rossby Financial LCC acquired a new position in shares of Agilent Technologies, Inc. (NYSE:A) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,698 shares of the medical research company’s stock, valued at approximately $228,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sienna Gestion lifted its holdings in shares of Agilent Technologies by 29.8% during the fourth quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock worth $10,537,000 after buying an additional 17,991 shares during the last quarter. Sequoia Financial Advisors LLC raised its stake in Agilent Technologies by 8.5% during the 4th quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock valued at $4,554,000 after purchasing an additional 2,664 shares during the last quarter. S.E.E.D. Planning Group LLC boosted its holdings in Agilent Technologies by 12.7% in the 4th quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock valued at $5,721,000 after purchasing an additional 4,805 shares during the period. Commonwealth Equity Services LLC grew its position in Agilent Technologies by 9.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company’s stock worth $5,892,000 after purchasing an additional 3,915 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in Agilent Technologies by 16.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company’s stock worth $6,621,000 after purchasing an additional 6,802 shares during the last quarter.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock opened at $105.19 on Tuesday. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $155.35. The firm’s 50-day moving average price is $122.90 and its two-hundred day moving average price is $133.54. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $29.99 billion, a price-to-earnings ratio of 24.18, a P/E/G ratio of 2.89 and a beta of 1.19.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Tuesday, April 1st. Agilent Technologies’s payout ratio is presently 22.76%.

Insiders Place Their Bets

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,638 shares of company stock valued at $731,229.

Analyst Ratings Changes

A has been the subject of several research reports. Robert W. Baird reduced their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. TD Cowen lifted their price objective on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Citigroup upped their target price on Agilent Technologies to $165.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Barclays lowered their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $146.25.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.